BCTX — Q3 FY2026 Financial Report Analysis

BriaCell Therapeutics, a clinical-stage cancer immunotherapy company with no product sales, lost $7.2 million in its fiscal third quarter of 2026 (the three months to April 30, 2026; BriaCell's fiscal year ends July 31). That is 17% more than a year earlier, driven by its pivotal Phase 3 breast cancer trial and a newer "off-the-shelf" program ramping up. The loss per share fell from $16.42 to $0.99, but only because the share count is roughly 19 times larger than a year ago after repeated stock sales and two reverse splits. The filing also repeats that there is "substantial doubt" about the company's ability to keep operating without raising more money.

At a glance

• $7.6 million quarterly cash burn (on average): operating cash outflow was $22.7 million over nine months. With $22.8 million of cash and short-term investments at April 30, that is roughly three quarters of runway before new funding.
• Loss per share down 94%, but not because results improved: the weighted share count rose from 373,067 to 7,250,487, so each share carries a much smaller slice of a loss that actually grew.
• $10.8 million spent on the Phase 3 Bria-IMT trial in nine months (+23%): the single biggest cost line and the asset the company's value rests on, with enrollment past 230 patients as of May 12, 2026.

The numbers

With no revenue, there is no operating margin to report. Per-share figures are adjusted for a 1-for-15 reverse split in January 2025 and a 1-for-10 reverse split in August 2025 (a reverse split merges several old shares into one new one, often to keep the share price above an exchange's minimum).

Where the money went

BriaCell's lead product, Bria-IMT, is a cell-based cancer vaccine given together with an immune checkpoint inhibitor (retifanlimab, a drug that takes the brakes off the immune system). It is in a pivotal Phase 3 study in metastatic breast cancer, the trial that would support an FDA approval if it succeeds, and has FDA Fast Track designation.

For the nine months to April 30, the 10-Q breaks clinical trial costs down as follows:

The company attributes the Phase 3 increase to "continued patient enrollment, expansion of clinical sites" and related lab and supply costs. The ninefold rise in Bria-OTS spending reflects manufacturing of Bria-BRES+ (breast cancer) and Bria-PROS+ (prostate cancer), the next-generation "off-the-shelf" versions meant to be matched to a patient's immune type without being custom-made. The FDA cleared Bria-BRES+ to start a Phase 1/2a study on May 6, 2026. A $2.0 million National Cancer Institute grant offset part of the cost: $0.94 million was received in the nine months and booked as a reduction of R&D expense.

What the headline numbers hide

• Per-share figures are distorted by dilution. The share count at April 30 (7.25 million) was 3.8 times the 1.88 million outstanding at July 31, 2025, after a $30.0 million unit offering in January 2026 that sold 5.37 million shares (or pre-funded warrants) at $5.59, each with a warrant attached. A further $4.7 million offering of 1.45 million shares at $3.25 closed on June 2, 2026, after the quarter ended, at a lower price.
• Cash conversion is close to the loss. Nine-month operating cash outflow ($22.7 million) was almost exactly the nine-month net loss ($22.8 million), so the loss is not being flattered by non-cash items. Only small non-cash items sit in the income statement (a $0.12 million warrant fair-value gain and a $0.14 million unrealised investment gain in the quarter).
• Cash went up only because of new stock sales. Cash and short-term investments rose from $17.9 million to $22.8 million over nine months, but only because financing brought in $27.9 million: the opening $17.9 million on its own would not have covered the $22.7 million operating outflow.
• Going-concern warning stands. The filing states that uncertainty over raising capital "casts substantial doubt on the Company's ability to continue as a going concern." The June raise adds roughly another half-quarter of spending at the current burn rate.
• Interest income is rising but small: $0.46 million over nine months, versus $0.09 million a year earlier, on the larger cash balance.

Takeaway: BriaCell's quarter is a funding story more than an operating one. It spends about $7.6 million a quarter, holds about three quarters of cash, and has been financing itself with stock sales at falling prices ($5.59 a unit in January, $3.25 a share in June). The Phase 3 Bria-IMT result is what decides whether that dilution was worth it.

Outlook

BriaCell gives no financial guidance. On timing, management said on December 9, 2025 that enrollment was "on track for 1H2026 topline data readout" from the Phase 3 study; the 10-Q, filed June 9, 2026, describes the trial as advancing "toward planned interim analyses" and does not report topline results. Investors should treat the readout timing as unconfirmed until the company announces data. The independent Data Safety Monitoring Board gave its fifth consecutive recommendation to continue the study in February 2026, which signals no safety problems but says nothing about whether the drug works.

Our view: costs will keep rising as the Phase 3 trial fills up and Bria-BRES+ enters the clinic, so quarterly burn above $7.6 million is more likely than below. That means another capital raise within the next few quarters unless a partnership brings in cash. The fiscal 2026 annual report (year ending July 31, 2026), due around October, will show how much the June offering extended the runway.

Source: BriaCell Therapeutics Form 10-Q for the quarter ended April 30, 2026, filed June 9, 2026.